134P - Effect of haematological adverse effects occuring during chemotherapy on response to treatment and progression free survival in advanced NSCLC

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Complications of Treatment
Non-Small-Cell Lung Cancer, Metastatic
Presenter Ahmed Nagy
Citation Annals of Oncology (2015) 26 (suppl_1): 29-44. 10.1093/annonc/mdv050
Authors A.A. Nagy, E. Fouad, K. Nasr, H. El-Ghazaly, A. Adel
  • Clinical Oncology And Nuclear Medicine, Ain Shams University Faculty of Medicine, 11566 - Cairo/EG



To evaluate whether haematological side effects occuring during chemotherapy have an impact on response to treatment and progression free survival in patients with advanced NSCLC.


This study was carried out in Clinical Oncology and Nuclear Medicine Department, Ain Shams University Hospitals during the period from January 2011 to June 2013. We enrolled 120 chemo-naïve patients with advanced NSCLC (75% aging less than 60 years, 70.8% males, 59.2% with performance status 2, 73.3% with nonsquamous histology and 79.2% presented with stage IV) to receive gemcitabine/cisplatin for 4-6 cycles. Response was assessed by Revised RECIST guidelines every 2 cycles and toxicity by NCI criteria for common toxicities every cycle.


Progressive disease occurred in 41.7% of the patients. Anaemia was observed in 45% of patients, thrombocytopenia was seen in 18.3% of patients, neutropenia was seen in 60.8% of patients and pancytopenia was observed in 16.7% of patients. A significant association was found between response to therapy and development of pancytopenia (Odds ratio = 3.047, 95% CI= 1.064-10.914, p = 0.031), however this could not be reflected as an effect on progression free survival (p =0.083).


Development of pancytopenia during treatment of NSCLC could be identified as a favorable prognostic factor to response to chemotherapy. A larger sample size with predominance of squamous histology could be used to evaluate the effect of gemcitabine / platinum on survival in future studies.


All authors have declared no conflicts of interest.